Aubagio (Multiple Sclerosis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Classification of Multiple Sclerosis 13
3.2 Symptoms 15
3.2.1 Prognosis 16
3.2.2 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis 18
4.2 Treatment Overview 21
4.2.1 Management of Acute Relapse 22
4.2.2 Treatment with Disease-Modifying Therapies 22
4.2.3 Symptomatic Therapies 25
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 Unmet Needs 30
6.2.1 Currently Available MS Drugs Only Provide Partial Benefits 30
6.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 31
6.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects 32
6.2.4 Effective Treatments for Progressive MS Are Still Elusive 33
6.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 34
6.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis 35
6.3 Unmet Needs Gap Analysis 36
6.4 Opportunities 37
6.4.1 Treatments for Progressive MS 37
6.4.2 Targeting Patients with Clinically Isolated Syndrome 37
7 Pipeline Assessment 38
7.1 Overview 38
7.2 Promising Drugs in Clinical Development 40
8 Aubagio (teriflunomide) 42
8.1 Overview 42
8.2 Efficacy 43
8.3 Safety 44
8.4 SWOT Analysis 45
8.5 Forecast 46
9 Appendix 48
9.1 Bibliography 48
9.2 Abbreviations 53
9.3 Methodology 55
9.4 Forecasting Methodology 55
9.4.1 Diagnosed MS patients 55
9.4.2 Percent Drug-Treated Patients 56
9.4.3 General Pricing Assumptions 56
9.4.4 Generic Erosion 57
9.5 Physicians and Specialists Included in This Report 57
9.6 Primary Research – Prescriber Survey 58
9.7 About the Authors 59
9.7.1 Analysts 59
9.7.2 Global Head of Healthcare 60
9.8 About GlobalData 61
9.9 Contact Us 61
9.10 Disclaimer 61